Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Acrigen Biosciences Inc
Profile last edited on: 1/4/2022      CAGE: 8B6M2      UEI: GVHYYXAME436

Business Identifier: High precision gene editing systems
Year Founded
2019
First Award
2020
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

202 Stanford Avenue
Kensington, CA 94708
   (619) 847-1193
   N/A
   www.acrigen.com
Location: Single
Congr. District: 08
County: Alameda

Public Profile

Acrigen Biosciences is structured around development of gene editing technologies specifically to improve the efficiency and enhance the safety of CRISPR-Cas based gene editing. The firm's technology is focused on utilizing "anti-CRISPR", or ACR proteins, to function as a deactivation of the Cas proteins to serve as a gene editing "off switch." This technology would help eliminate unwanted side effects and unanticipated editing in a patient by providing and more focused and controlled way to us CRISPER based gene editing.

Extent of SBIR involvement

User Avatar
Phase I Awards
4
Phase II Awards
1
Conversion Rate
25.00%
Phase I Dollars
$990,291
Phase II Dollars
$1,000,000
Total Awarded
$1,990,291

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $256,580
Project Title: Enhancing CRISPR-mediated homology-directed repair using anti-CRISPR proteins
2022 2 NSF $1,225,000
Project Title: Development of a safe gene editing system via CRISPR-Cas and Cas inhibitor co-delivery
2021 1 NIH $256,580
Project Title: Development of Safe in Utero Gene Editing Technology in Mice
2020 1 NIH $252,131
Project Title: Discovery And Applications Of Crispr-Cas Inhibitor Proteins

Key People / Management

  David Rabuka -- Co-Founder CEO and President

  Joseph Bondy-Denomy -- Founder and SAB chair

  Trevor Collingwood -- Chief Technology Officer

  Tippi Mackenzie -- Advisor & SAB Member

  Michael Schelle -- VP of Research and Operations

Company News

There are no news available.